US2019262422A1PendingUtilityA1

Hypoxia-induced mitogenic factor

Assignee: UNIV JOHNS HOPKINSPriority: Feb 7, 2003Filed: Jan 9, 2018Published: Aug 29, 2019
Est. expiryFeb 7, 2023(expired)· nominal 20-yr term from priority
A61P 9/00A61P 43/00A61P 9/12A61P 27/02A61P 11/00A61P 17/02A61K 38/1709A61K 38/22A61K 48/00C07K 16/18C07K 2317/20C07K 16/22A61K 39/3955C07K 14/575A61K 9/0019G01N 33/5061
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.

Claims

exact text as granted — not AI-modified
1 - 17 . (canceled) 
     
     
         18 . A method of treating diabetic retinopathy, comprising: administering an antibody which specifically binds to a protein comprising the sequence of SEQ ID NO: 1 to a patient in need thereof, in an amount sufficient to relieve symptoms of diabetic retinopathy. 
     
     
         19 . The method of  claim 18  wherein the antibody is administered directly to the eye. 
     
     
         20 . The method of  claim 18  wherein the antibody is administered systemically. 
     
     
         21 - 27 . (canceled)

Join the waitlist — get patent alerts

Track US2019262422A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.